Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RGBP will have the same funding options as they did after 2 years of moving forward the science of HemaX: None!
RGBP and Koos has a sizeable public record..... PR machine, financials, technicals etc
Always, including the RGBP, pour over that public history of any investment. If you do not have time, task somebody to do it for you.
RGBP and Koos can not hide from their public record. RGBP and Koos count on people.not thoroughly vetting them. RGBP’s track record takes a reader of their history down the following mega-road;
RGBP’s publicly stated purpose for spinning off from BioMatrix in a word; HemaX. Looking at the financials, of BioMatrix, HemaX had no PR value under that umbrella. Poof..... RGBP was conceived.
Once HemaX’s value ran out, Poof.... another mega-hypothesis a kin to HemaX was trotted out via the PR route. Once this mega-hypothesis dries up, What will be the next Poof? A new mega-spin off, Or a new mega/hypothesis.
This is, of course “Opinion” based on the DD of RGBP’s public record.
Activating NR2F6 potentially leads to inhibiting the immune system and should lead
to therapies... is “a proposition assumed as a premise in an argument.”
The world is literally being asked to buy this hypothetical proposition by RGBP’s CEO
Before you buy the mega-hypothesis, scrutinize the seller of this stuff. Is RGBP’s CEO a proven seller?
From what my intern has reported, the only thing proven is the CEO cashing a large paychecks for a long time without a dimes worth of sales, no products developed, and never even bringing a potential product into phase 1 testing.
Koos sells the “should lead” like HemaX should ........
Should’s = Trips
Beware of the seller of hypothesis. Buy the proven sellers elsewhere
“Correction: Regen BioPharma previously disclosed, in error, that "inhibiting NR2F6 is believed to provide potential therapies for treating autoimmunity." The statement should read: Activating NR2F6 potentially leads to inhibiting the immune system and should lead to therapies for treating autoimmunity diseases such as lupus.”
NR2F6 is NOT Mega Science or even science. In the world of science, this would be nothing more than a “HYPOTHESIS”!!!!!
NR2F6 is a mega-hypothesis!
RGBP stock price is down, NOT UP: .25-.15-.10-.05-.04-.03!
Smells like Roses:
RGBP’s current financials
RGBP’s past financials
RGBP’s HemaX con
RGBP’s parent BMSN
RGBP’s ceo’s Track record
Right, it isn’t a porta John.
It’s the David Dumspter and his Kooslaid Drinkers
The only thing weak here is RGBP stock price, 1’s.
The only thing twisted is the belief that the insolvent RGBP has the resources to navigate phase 1
(about$4-5 million) or the entire 3 phases ($40-50 million). RGBP ain’t gonna happen in the real world. The only guarantee is that the RGBP konman maintains his lifestyle!
2005-2018 RGBP & BSMN "PR" History:
I asked the intern that put this together for me, "Would you invest in this company, CEO based on his this PR history?" What do you think she replied?
Statement 1:
Regen BioPharma, Inc. Reports Success of its NR2F6 Small Molecule Screening Program for Treating Autoimmune Diseases
PR Newswire August 30, 2018
David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc. added, "This is exciting for Regen to reach this point in its goal for developing therapies that treat autoimmune diseases. These compounds recently identified should provided us the basis to further refine our screening for successful antagonists in the development of immunologically based cancer therapies."
Statement 2:
SAN DIEGO, July 12, 2017 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), today reported continued progress in developing small molecule drugs that activate and inhibit NR2F6. The Company reports that using a focused compound library and Regen's patented screening methodology, it has identified a dynamic new chemical compound series that modulates NR2F6.
"I am very pleased that our science continues to advance positively," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "ChemDiv's expertise in compound optimization has been a great asset as we refine our small molecule drug development program. We continue to expect 2017 to be an extremely important year in Regen's history. Studies were conducted for Regen by ChemDiv, Inc. (an internationally recognized contract research organization) which has been retained by Regen."
Statement 3:
SAN DIEGO, December 11, 2017 /PRNewswire/ --
Regen BioPharma, Inc. (RGBP) and (RGBPP) today announced filing a patent application covering composition of matter and methods of use related to molecules identified in its small molecule program that activate and inhibit NR2F6 ("Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans").
"We continue to ensure that the intellectual property that is generated by Regen is protected so that our shareholders can materially benefit from the commercialization of this technology," said David Koos, Ph.D., CEO of Regen BioPharma, Inc.
Statement 4:
SAN DIEGO, November 16, 2017 /PRNewswire/ --
18 months ago, Regen BioPharma Inc. (RGBP)(RGBPP) commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient's own immune system. Regen is also engaged in the identification of small molecules which activate the NR2F6 nuclear receptor that can be utilized to develop small molecule therapies for autoimmune disorders
"The rationale for activating the NR2F6 nuclear receptor (also known as a checkpoint) is straightforward - if inhibiting the checkpoint activates the immune system and thus helps kill cancer cells, then conversely, activating the checkpoint should suppress the immune system and thus be useful in diseases where the immune system is over-activated, such as rheumatoid arthritis, lupus, colitis and many other autoimmune diseases," says David Koos, Ph.D., Chairman and CEO of Regen. "Our program stands out because we are working with small molecules delivered in pill form. Other biotechnology companies are focused on antibodies that have much more cumbersome delivery methods (hospital stays with IV injections, etc.). The benefits of small molecules are many, including cost of manufacturing, flexibility in dosing and routes of administration, potential control of toxicity and intellectual property protection."
Statement 5:
17 Nov 2015
Shares in Regen BioPharma gained ground on Tuesday as it advanced further its HemaXellerate drug, which is aimed at restoring healthy blood cells.
David Koos, chairman and chief executive of Regen said: "Because HemaXellerate is a personalized cell therapy product aimed at addressing an unmet medical need, we are in agreement with the FDA in performing the most rigorous safety and efficacy experiments in order to deliver this promising product to patients who at the moment have no other options."
Statement 6:
SAN DIEGO, CA--(Marketwired - Sep 10, 2014) - Regen BioPharma Inc. ( OTCBB : RGBP ) announced today the outcome of a telephonic meeting with the FDA regarding IND #15376 for use of HemaXellerate in the treatment of aplastic anemia. The subject of this meeting with FDA cell therapy experts was the Company's existing experimental data and the requirement for additional safety data with regard to the IND application.
"Our first concern in product development is safety and the well being of patients participating in our planned future clinical trial. By leveraging the experience of the FDA and their cell therapy experts, we are confident that we will develop a strong product that will help aplastic anemia patients, which are currently without viable treatment options," said David Koos Chairman and CEO of Regen BioPharma Inc.
Statement 7:
SAN DIEGO, CA--(Marketwired - Oct 8, 2014) - Regen BioPharma Inc. ( OTCBB : RGBP ) announced today the filing of an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to initiate a clinical trial assessing safety and therapeutic effects of dCellVax in patients with metastatic breast cancer. dCellVax is an immunotherapeutic product that utilizes the patient's own immune cells to attack the tumor. Success of dCellVax in the proposed trial is anticipated to pave the way for expanded use of dCellVax in a variety of other tumors. Advantages of cancer immune therapies include: a) lack of toxicity; b) ability to attack tumor metastasis; and c) generation of immunological memory, which protects the body from recurrence of the tumor.
"Today marks a significant milestone for Regen BioPharma Inc., by filing our second IND application, we are accomplishing our original mission statement, which was to accelerate translation of nascent intellectual property from academia into viable therapeutic products," said David Koos, President and CEO of Regen BioPharma. "We are thankful for Dr. Wei-Ping Min and his team at the University of Western Ontario, who have worked diligently with us over the last 18 months in making this IND application a reality."
Statement 8:
Aug 13, 2013 Regen: a licensing agreement with Benitec Biopharma (ASX: BLT) for vaccines that can be developed using gene technology
According to a news release, Dr. David Koos, Regen's CEO, said, the work could lead to "an immune-based, non-toxic, cancer treatment initially targeting breast cancer."
Statement 9:
August 19, 2009 Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN) announced today its majority owned subsidiary, Entest BioMedical unit (OTCBB: ENTB), has filed a patent application for the use of adipose derived stem cells in the treatment of Chronic Obstructive Pulmonary Disease (COPD). BMSN is excited with the progress achieved by Entest BioMedical, Inc. (OTCBB: ENTB) in identifying diseases it believes will be treatable through Stem Cell Therapy.
Steven Josephs, PhD. noted, “The approach is intended at the very least to alleviate the chronic inflammation in COPD. This is done by using agents known to coax adult stem cells that are delivered to the diseased lung tissue (blood monocyte cells) to release cytokines (biologically active molecules) which in addition to the anti-inflammatory effects may actually promote the regeneration of functional lung tissue.”
Statement 10:
November 30, 2005 Bio-Matrix Scientific (Pink Sheets: BMXP) has announced the development of a Veterinary Stem Cell Instrumentation for stem cell therapy. Bio-Matrix unveiled prototypes of its veterinary stem cell instrumentation at the American College of Veterinary Surgeons' Symposium in San Diego
Bio-Matrix Chairman David Koos noted: "Veterinary medicine is well-advanced in stem cell therapy and regenerative medicine for animals, compared to the current known and FDA approved human applications. The production of these instruments should ultimately lead to treatment applications for human subjects not currently available in the United States."
Mega 1’s is nothing to yawn at. Just imagine astute zero’s
Sorry to hear that. I guess nothing more than potential here
As well, everybody should easily see RGBP’s price over the last two years!
.14
.12
.08
.06
.04
.02
Now 1’s
When will trips arrive here..... by Christmas? That would be a great gift for astute fans of science. LOL
"Does anyone else even read the financials? "
Yes, the investor that never invested in RGBP. Lilly probably spent a few minutes on it LOL
and the super mega guys... well... they imply that their understanding of the past and present RGBP financial situation leads them to believe in super mega RGBP$$.
My intern told me today that RGBP's Konman makes $300k between RGBP and his spin off (the transition to the next one, after the postmortem on RGBP is complete).
It seems logical right? Insolvency = RGBP$$
what will happen first? HemaX starts Phase 1 trials? Massive Dilution? or Toxic Funding?
Evaluating RGBP doesn't require any poetry, just common sense. RGBP; as well as the preceding leaderless ships has been at this since 2001 and NOT a SINGLE PRODUCT has made it to market, successfully completed Phase 3, or even Phase 1.
RGBP was even granted the go ahead for Phase 1 with HemaX and could NOT even begin that process. The sole stated purpose of the spin off to RGBP was HemaX.
If you want to understand the direction of RGBP, DD on these companies run by Konman Koos makes it clear.
Career History
Chairman/Pres/CEO/Interim CFO Entest Group Inc, 2/2018-PRESENT
Chairman/CEO/Secy/Treasurer Zander Therapeutics Inc, 2/2017-PRESENT
Chairman/CEO Regen Biopharma Inc, 4/2015-PRESENT
Chairman/Pres/CEO/Acting CFO/SecyBio-Matrix Scientific Group Inc, 6/2006-PRESENT
Chairman/Pres/CEO/Interim CFOEntest Biomedical Inc, 8/2011-2/2018
Chairman/Pres/CEO/Interim CFO/SecyZander Therapeutics Inc, UNKNOWN-2/2017
Chairman/Pres/CEO/Treasurer/SecyRegen Biopharma Inc, 2/2015-4/2015
Chairman/Pres/CEO/Interim CFO/Treasurer/SecyRegen Biopharma Inc, 5/2013-2/2015
Chairman/CEO/Interim CFO/Treasurer/SecyRegen Biopharma Inc, 4/2012-5/2013
Chairman/President/CEO/SecyEntest Biomedical Inc, 3/2010-8/2011
Chairman/Pres/CEO/CFO/SecyEntest Biomedical Inc, 7/2009-3/2010
President/Managing DirectorCell Source Research Inc, 12/2001-UNKNOWN
RGBP...Then (HemaX PR) and Now (LOL)
December 11th, 2013
In contrast to previous experiments reported by the company, in this set of experiments, recipient animals possessed an intact immune system, implying that the HemaXellerate I™ product does not trigger adverse immune reactions.
"These data are part of the FDA requested experiments, which we are compiling to address the second series of questions that the FDA has asked us subsequent to our filing of IND #15376 for use of HemaXellerate I™ in the treatment of drug refractory aplastic anemia." Said David Koos, CEO of Regen. "By leveraging our SAB members, collaborators such as Dr. Wei-Ping Min, and contractors such as Cook General Biotechnology, who manufactures GMP-grade HemaXellerate I™, the Company believes it is well positioned to develop the product as the first regenerative medicine solution for drug resistant aplastic anemia, an indication which qualifies for Orphan Drug Status."
SAN DIEGO, September 25, 2015 /PRNewswire/
Final Experiments Requested by FDA Completed
"Safety of patients is our first priority. We are grateful to the FDA for advising us on the design of the completed safety studies, which will ensure we deliver a high quality product to patients in the proposed clinical trial," said David Koos, Chairman and CEO of Regen BioPharma.
SAN DIEGO,July 23, 2018/PRNewswire/ –
"Drug safety is always the number one concern of any drug development process," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "We are very pleased to see that this drug is safe in mice. It is another major milestone we have passed with this drug."
WOW.... RGBP's HemaX is now PROVEN 100% not to make patients sick as it was never used in phase 1 trials. Prediction, RGPB's latest will be proven in the same manner with the same results as HemaX.
What was RGBP dividend starting out at based on HemaX, 00.25? The only people being sickened are the one's that lose out on RGBP's PR based centric operations.
"Yep. Science. And cheap. And suckers who keep selling me shares for cheap. "
RGBP = 0.0197
RGBP wasn't bought out by Lilly
RGBP wasn't bought out when HemaX hit the rock pile
The other Koos companies have hit the rock pile without being bought out.
Frankly, if any business saw value in RGBP's Mega Science, they would let this insolvent operation go under and buy it for pennies on the dollar. But, like RGBP's HemaX, its all unproven hype.
Most likely fate for RGBP is the same as the Kons before and he will buy dusty patents of the shelf of some university and start up, another, all over AGAIN!
Alphabet’s portfolio doesn’t include anything like today’s RGBP’s trade volume of 45.... RGBP expert was it a misprint?
RGBP rocks at less than a nickel....
HemaX is their phase one trial blueprint....
Koos laughing all the way to the bank......
AND
Mega
Make
Entest
Great
Again!
Your typical successful OTC conglomerate. RGBP is just a cog in the wheel of fortunes. May the conglomerate deliver for all the mega RGBP believers LOL
WOW is absolutely correct.
Prefer'd down -50% at .01. HUH, RGBP common at 2's and RGBPP is .01! If you don't want to be in on RGBP prefer'd, what's that say about the RGBP common?
RGBP is upside down; And this signal sure looks like double dip zero's coming for RGBP common.
excuse me, Super Mega Double Dip zero's for RGBP common.
RGBP paying for PR’s
The super Mega Science is that good
“Small Cap Solutions, LLC has received ($1000.00) cash from Value Quest, Inc. for investor relations services rendered for Regen BioPharma, Inc. . “
RGBP and Koos believes in the Mega Science:
“Small Cap Solutions, LLC has received ($1000.00) cash from Value Quest, Inc. for investor relations services rendered for Regen BioPharma, Inc. . “
Listen to Sid and SanDiegoAlan! Look at those guys past posts. They are all over this con!
BTW they tell it like it is without being paid off. Super Mega Investor Value for free!
Hey look; it’s RGBP’s CEO, Prez, PhD’s official statement regarding RGBP’s science backed, patented compound HemaX!
SidV, spend as little time here as possible, so I missed it....... I always wondered if the Kon Man released an official statement “why they quit on that product after FDA green lighted it for a trials?”
The NEWS is here! The Kooze Koin..... a utility coin utililizing Super Mega blockchain technology for the sole purpose of funding (furthering) the Kooze Kon. 100 Trillion Kooze Koins of which Mgmt owns a meager
10 billion.
Super Mega Nonsense!
Super Mega Science paying off big time! It’s still above trips!
________________________________________________________________________________________
“Right on! But most critics on here don't want to let facts get in the way of their uninformed opinions.
Go RGBP!!!”
________________________________________________________________________________________
This POS traded 23 times today. It trades 10, 15, 20, 25 times a day in the entire US market. Think about it. A local Dominos gets more orders in an hour. FAT chance that the market is impressed by the bottom feeder science here. And to claim Big Gains on so few trades is delusional.
The last drug Hexa.... made it way past this point. The ones before RGBP same deal. In this phase of the con, he keeps the targets dangling on the low grade science for as long as possible until the con is suddenly dropped and the cycle begins all over with a new batch of willing targets.
He’s been doing it for well over a decade.
Ref: Goldstrike
Nothing wrong with this thinking, however, SidVicious might be trying to communicate a deeper point rather than simple logic: Fail with your own money, not other people's money over such a long period of time!
Nowhere does this guy tell any investor how much money he has hosed past investors out of. If he were to publicly post the numbers sucked out of past investors, simple logic equates any involvement here as simply flushing money down the toilet. They are laughing all the way to the bank and/or boat!
Let me offer a different, firsthand perspective .
As a kid in the 60's and teen in the 70''s, we got tons more exercise. We played outside from morning till dusk. There were only 3 major tv channels geared for adults. I didn't get cable until I was almost 30 and bought my first tv.
As a 22+ year football coach, one of my roles was strength training and diet. The first thing that might surprise a person today is caloric intake. In 1900 (100 years ago) the average per capita intake was 3500 calories a day. By 2000, here comes the surprise, the average per capita intake in the USA was 3800 calories. Looking at our physical health, you woulda thought 5000+
The two big changes I lived through. Pre 1980's, work was manual labor. Not anymore. Work was 16 hours. Then 12 hours. Then 10 hours. Then 8 hours a day.
In the end, our bodies need both low and high intensity exercise, everyday. It's call evolution, and our modern on demand society has only been around 75 years. Calories don't care. They are either converted to energy or stored. It's that simple.
The obesity/diabetes etc crisis began in the early 1980's. That is when cable TV got hooked up nationwide. Noe, it's devices and gaming. Kids today do Not or could not play 10, 12 hours a day. They do not have the stamina b/c they sit around to much, including my twins. Every chart I have ever seen at conditioning seminars is hockey stick up beginning the in 1980's.
BTW, I am in big time on ENDV. What a breakthrough, IF..... seen a lot of IF's in my time
Happy squats and power cleans! lol
Yah, I was an early investor in X. You forgot to mention the ceo promising never R/S, right before the R/S. That wasn't a scare tactic, but investor wealth destruction.
If people didn't sell at $.60+
then they got these results. Sorry for you guys, but taking the profit is the name of this game.
Don't be sorry. Made a boat load of $ on this one.
The only thing that worries me jumping back in was
the sell order experience, here.
Couldn't get out the other day at .26. B/C it was
my first experience with this one, i used a market
order. When the big block did not get filled
in a timely manner, had to split it up into
blocks of 25K and 50K.
And even some of those blocks of shares took
a long while to be filled.
this is one of the nags keeping me out right now.
Thnx Maverick. Options action broadly predicts high probability that under $.50 in next three weeks (expiration 10/18)
You buy a Put option (naked short) or a Put spread
Have no upside interests in NBG. With that said, did you guys get that load of..... that bogus resume? my 10 year old quadruplets could smell that one for what it was! :)
Going to zero?
I am not familiar with NBG. After reading 2 investor notes, I came for a look.
They went something like this: Good Bank/Bad Bank concept.
A new NBG will be set up (different tax ID Etc). All the good paper (assets etc) to be moved over to the Good Bank. And, To be recapitalized and publicly traded. The existing Bad NBG will only hold the bad paper & underwater assets A LA the fed 2008. It will be taken off the trading floor, hence, shareholder value wiped out. The bad bank will hold the bad paper until some time in future when prices rise and paper can be sold.
This possibility has not been publicly aired. After reading these investor notes, am considering a short here if possible
Nothing to be sorry about:
44 on about 200 million shares
38 on about 30 million shares
Equals a healthy pullback while the uptrend continues!